Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
| Autor: | Bo Wängberg, Gertrud Berg, Johanna Svensson, Maria E. H. Larsson, Eva Forssell-Aronsson, Peter Bernhardt |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Urology Octreotide Renal function Neuroendocrine tumors Kidney 177Lu-DOTATATE therapy Neuroendocrine tumours Dosimetry Internal medicine Organometallic Compounds medicine Humans Radiology Nuclear Medicine and imaging Aged Radiotherapy business.industry Kidney metabolism General Medicine medicine.disease Renal Reabsorption Radiation therapy Neuroendocrine Tumors Blood Endocrinology medicine.anatomical_structure Tolerability Radiology Nuclear Medicine and imaging Radionuclide therapy Original Article Female PRRT Radiopharmaceuticals business medicine.drug |
| Zdroj: | European Journal of Nuclear Medicine and Molecular Imaging |
| ISSN: | 1619-7089 1619-7070 |
| DOI: | 10.1007/s00259-015-3001-1 |
| Popis: | Purpose Peptide receptor radionuclide therapy (PRRT) has become an important treatment option in the management of advanced neuroendocrine tumours. Long-lasting responses are reported for a majority of treated patients, with good tolerability and a favourable impact on quality of life. The treatment is usually limited by the cumulative absorbed dose to the kidneys, where the radiopharmaceutical is reabsorbed and retained, or by evident haematological toxicity. The aim of this study was to evaluate how renal function affects (1) absorbed dose to the kidneys, and (2) the development of haematological toxicity during PRRT treatment. Methods The study included 51 patients with an advanced neuroendocrine tumour who received 177Lu-DOTATATE treatment during 2006 – 2011 at Sahlgrenska University Hospital in Gothenburg. An average activity of 7.5 GBq (3.5 – 8.2 GBq) was given at intervals of 6 – 8 weeks on one to five occasions. Patient baseline characteristics according to renal and bone marrow function, tumour burden and medical history including prior treatment were recorded. Renal and bone marrow function were then monitored during treatment. Renal dosimetry was performed according to the conjugate view method, and the residence time for the radiopharmaceutical in the whole body was calculated. Results A significant correlation between inferior renal function before treatment and higher received renal absorbed dose per administered activity was found (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|